Three-year outcomes of preserflo MicroShunt with mitomycin C for uveitic glaucoma

To report efficacy and outcomes of Preserflo MicroShunt surgery in patients with uveitic glaucoma at a tertiary center.

Retrospective cohort study.

Consecutive patients with uncontrolled uveitic glaucoma who underwent Preserflo MicroShunt surgery with a minimum of 2 years of follow-up. Baseline characteristics, pre-operative and post-operative intraocular pressure (IOP), number of glaucoma medications, visual acuity, and adverse events were recorded.

A total of 48 eyes with uveitic glaucoma underwent Preserflo MicroShunt with 0.4-0.5 mg/mL mitomycin C (MMC) were followed up at 2 years post-operation and 38 eyes at 3 years post-operation. The mean age was 51 ± 17 (21-84) years, and 27 (56.3%) were female. The mean baseline IOP of 29 ± 8 (range: 14-45) mmHg was reduced at each year post-operatively (P < 0.0001). The mean post-operative IOP at 1 year was 12.5 ± 5.0, at 2 years, it was 11.4 ± 4.8, and at 3 years, it was 13.6 ± 6.8 mmHg. The mean number of pre-operative glaucoma medications was 3.2 ± 1.3 (range: 0-5) compared with 0.4 at 1 year, 0.3 at 2 years, and 0.6 at 3 years (P < 0.0001). Adverse events included hypotony (two eyes), required revision of Preserflo MicroShunt (six eyes), and required further glaucoma surgery (six eyes). At the last follow-up visit, the overall success rate (IOP ≤ 21 mmHg and a 20% reduction ± medication) was 75%.

Our study showed good IOP control with Preserflo MicroShunt surgery at 3 years for patients with uncontrolled uveitic glaucoma.